MCID: NRF002
MIFTS: 74

Neurofibromatosis malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Ear diseases, Fetal diseases, Cancer diseases, Eye diseases, Cardiovascular diseases, Nephrological diseases, Skin diseases

Aliases & Classifications for Neurofibromatosis

About this section
Sources:
10Disease Ontology, 68Wikipedia, 45NIH Rare Diseases, 46NINDS, 47Novoseek, 12DISEASES, 35MedlinePlus, 21GeneReviews, 22GeneTests, 23Genetics Home Reference, 51Orphanet, 36MeSH, 65UMLS, 24GTR, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Neurofibromatosis:

Name: Neurofibromatosis 10 68 45 46 47 12 35
Bilateral Acoustic Neurofibromatosis 68 21 45 22 23 51
Neurofibromatosis 1 10 21 22 23 36 65
Von Recklinghausen Disease 68 21 45 22 23
Central Neurofibromatosis 10 21 22 23 51
Neurofibromatosis Type Ii 68 21 45 22 23
Neurofibromatosis Type 2 10 45 23 47 51
Neurofibromatosis 2 21 22 23 36 65
Nf2 21 45 22 23 51
Peripheral Neurofibromatosis 10 68 22 23
Neurofibromatosis Type 1 10 45 23 47
Nf1 21 45 22 23
Banf 68 22 23
Von Recklinghausen's Neurofibromatosis 21 22
Schwannoma, Acoustic, Bilateral 68 23
Recklinghausen Disease, Nerve 68 23
Familial Acoustic Neuroma 68 65
Neurofibromatosis Type Iv 10 24
Vestibular Schwannoma Neurofibromatosis 22
 
Type Iv Neurofibromatosis of Riccardi 10
Recklinghausen's Neurofibromatosis 10
Acoustic Schwannomas, Bilateral 22
Neurofibromatosis Central Type 45
Acoustic Schwannomas Bilateral 45
Acoustic Neurinoma Bilateral 45
Von Recklinghausen's Disease 46
Multiple Neurofibromatosis 68
Acoustic Neurofibromatosis 10
Familial Acoustic Neuromas 23
Von Reklinghausen Disease 10
Recklinghausen's Disease 45
Neurofibromatosis Type I 68
Neurofibromatosis Type 4 10
Type 1 Neurofibromatosis 45
Neurofibromatoses 65
Nf 2 22
Nf 1 22

Characteristics:

Orphanet epidemiological data:

51
bilateral acoustic neurofibromatosis:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Finland); Age of onset: All ages


Classifications:



External Ids:

Disease Ontology10 DOID:8712
Orphanet51 637
ICD10 via Orphanet28 Q85.0
MESH via Orphanet37 D009464, D016518
UMLS via Orphanet66 C0027832, C0027859
UMLS65 C0027831, C0027832, C0162678 C0220695, C1136041, more

Summaries for Neurofibromatosis

About this section
MedlinePlus:35 Neurofibromatosis is a genetic disorder of the nervous system. it mainly affects how nerve cells form and grow. it causes tumors to grow on nerves. you can get neurofibromatosis from your parents, or it can happen because of a mutation (change) in your genes. once you have it, you can pass it along to your children. usually the tumors are benign, but sometimes they can become cancerous. there are three types of neurofibromatosis: type 1 (nf1) causes skin changes and deformed bones. it usually starts in childhood. sometimes the symptoms are present at birth. type 2 (nf2) causes hearing loss, ringing in the ears, and poor balance. symptoms often start in the teen years. schwannomatosis causes intense pain. it is the rarest type. doctors diagnose the different types based on the symptoms. genetic testing is also used to diagnose nf1 and nf2. there is no cure. treatment can help control symptoms. depending on the type of disease and how serious it is, treatment may include surgery to remove tumors, radiation therapy, and medicines. nih: national institute of neurological disorders and stroke

MalaCards based summary: Neurofibromatosis, also known as bilateral acoustic neurofibromatosis, is related to neurofibromatosis, familial spinal and watson syndrome, and has symptoms including tinnitus, dizziness and sensorineural deafness/hearing loss. An important gene associated with Neurofibromatosis is NF2 (Neurofibromin 2 (Merlin)), and among its related pathways are pilocytic astrocytoma and G-protein signaling M-RAS regulation pathway. Affiliated tissues include brain, bone and skin, and related mouse phenotypes are hearing/vestibular/ear and limbs/digits/tail.

Genetics Home Reference:23 Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. The most common tumors associated with neurofibromatosis type 2 are called vestibular schwannomas or acoustic neuromas. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition.

NIH Rare Diseases:45 Neurofibromatosis (nf) is a genetic condition that causes tumors to develop in the nervous system. there are three types of neurofibromatosis that are each associated with unique signs and symptoms:neurofibromatosis type 1 (nf1) causes skin changes (cafe-au-lait spots, freckling in armpit and groin area); bone abnormalities; optic gliomas; and tumors on the nerve tissue or under the skin. signs and symptoms are usually present at birth. neurofibromatosis type 2 (nf2) causes acoustic neuromas; hearing loss; ringing in the ears; poor balance; brain and/or spinal tumors; and cataracts at a young age. it often starts in the teen years. schwannomatosis causes schwannomas, pain, numbness, and weakness. it is the rarest type. all three types of nf are inherited in an autosomal dominant manner. there is no cure for neurofibromatosis. treatment is aimed at controlling symptoms and may include surgery to remove tumors, radiation therapy and/or medicines. last updated: 7/27/2015

NINDS:46 The neurofibromatoses are genetic disorders that cause tumors to grow in the nervous system.

Wikipedia:68 Neurofibromatosis (NF) refers to several genetically inherited conditions that are clinically and... more...

GeneReviews summary for NBK1201

GeneReviews summary for NBK1109

Related Diseases for Neurofibromatosis

About this section

Diseases in the Neurofibromatosis family:

Neurofibromatosis, Type 1 Neurofibromatosis, Type 2
Neurofibromatosis Type 1 Due to Nf1 Mutation or Intragenic Deletion

Diseases related to Neurofibromatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 495)
idRelated DiseaseScoreTop Affiliating Genes
1neurofibromatosis, familial spinal32.7MLH1, NF1, PMS2, SDHB, SDHC, SDHD
2watson syndrome31.1NF1, PTPN11
3paraganglioma and gastric stromal sarcoma30.3SDHB, SDHC, SDHD
4colon adenoma30.1MLH1, PMS2
5pleomorphic xanthoastrocytoma29.7HRAS, NF1, PTPN11
6pheochromocytoma29.5NF1, RET, SDHB, SDHC, SDHD
7gastrointestinal stromal tumor29.4KIT, NF1, PDGFRA, SDHB, SDHC, SDHD
8chronic inflammatory demyelinating polyradiculoneuropathy29.1HRAS, RET
9meningothelial meningioma29.1EZR, NF2
10leukemia, acute myelomonocytic, somatic, somatic28.8HRAS, NF1, PDGFRA, PTPN11, SPRED1
11cavernous hemangioma28.6HRAS, PDGFRA, RET
12von hippel-lindau syndrome28.6NF1, RET, SDHB, SDHC, SDHD
13cellular schwannoma28.1EZR, KIT, NF1, NF2, PDGFRA
14neurofibromatosis-noonan syndrome12.3
15neurofibromatosis, type 112.3
16neurofibromatosis, type 212.3
17neurofibromatosis type 1 due to nf1 mutation or intragenic deletion12.0
18legius syndrome11.9
19schwannomatosis11.8
20chromosome 17q11.2 deletion syndrome, 1.4mb11.4
21autosomal dominant café au lait spots11.1
22duodenal carcinoid syndrome11.1
23neurofibroma10.9
24hyaline fibromatosis syndrome10.9
25malignant peripheral nerve sheath tumor10.8
26interstitial nephritis, karyomegalic10.8NF1, SPRED1
27melanotic neurilemmoma10.7NF1, NF2
28doyne honeycomb degeneration of retina10.7MLH1, PMS2
29neurofibrosarcoma10.6
30adult fibrosarcoma10.6NF1, NF2
31junctional epidermolysis bullosa10.5KIT, NF1, NF2
32sensory system cancer10.5KIT, NF1, NF2
33pilocytic astrocytoma10.4
34optic nerve glioma10.4
35familial stomach cancer10.4SDHB, SDHC, SDHD
36neuroaxonal dystrophy renal tubular acidosis10.4SDHB, SDHC, SDHD
37extraneural perineurioma10.4KIT, PDGFRA
38gigantism10.4
39glycogen storage disease ib10.4SDHB, SDHC, SDHD
40moyamoya disease10.4
41glioblastoma10.4
42constant exophthalmos10.4SDHB, SDHC, SDHD
43aggressive systemic mastocytosis10.3KIT, PDGFRA
44multiple chemical sensitivity10.3KIT, PDGFRA
45plexiform neurofibroma10.3
46megalocornea10.3KIT, SPRED1
47acoustic neuroma10.3
48hemimegalencephaly10.3
49rhinitis10.3KIT, PDGFRA
50prostate leiomyosarcoma10.2KIT, PDGFRA, SDHD

Comorbidity relations with Neurofibromatosis via Phenotypic Disease Network (PDN):


Neurofibromatosis, Type 1Acute Cystitis

Graphical network of the top 20 diseases related to Neurofibromatosis:



Diseases related to neurofibromatosis

Symptoms for Neurofibromatosis

About this section

Symptoms:

 51 (show all 25)
  • tinnitus
  • dizziness
  • sensorineural deafness/hearing loss
  • ataxia/incoordination/trouble of the equilibrium
  • autosomal dominant inheritance
  • cataract/lens opacification
  • skin tumors/lumps/epidermal cysts
  • facial pain/cephalalgia/migraine
  • facial palsy
  • corneal clouding/opacity/vascularisation
  • retinal vascular anomalies/retinal telangiectasia
  • mild visual loss/impaired visual acuity
  • follicular/erythematous/edematous papules/milium
  • cafe-au-lait spot
  • cutaneous neurofibromas/facial angiofibromas/koenen tumors
  • subcutaneous nodules/lipomas/tumefaction/swelling
  • cranial nerves palsy
  • cranial hypertension
  • abnormal gait
  • sensitive trouble/deficit
  • alexia/agraphia/writing/reading troubles
  • central nervous system/peripheral nerves neoplasm/tumor/carcinoma/cancer
  • glial tumor/glioblastoma
  • meningioma
  • benign tumor of the brain/nervous system

HPO human phenotypes related to Neurofibromatosis:

id Description Frequency HPO Source Accession
1 lisch nodules HP:0009737
2 atypical neurofibromatosis HP:0007524

UMLS symptoms related to Neurofibromatosis:


sleeplessness, vertigo/dizziness, hyperexplexia, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain, ataxia, neuralgia

Drugs & Therapeutics for Neurofibromatosis

About this section

Drugs for Neurofibromatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 178)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PalbociclibapprovedPhase 4, Phase 185571190-30-211431660, 5005498
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
 
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
Palbociclib Isethionate
S1116_Selleck
2
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 1, Phase 0179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
3
Sorafenibapproved, investigationalPhase 4, Phase 2, Phase 1671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
4
Sunitinibapproved, investigationalPhase 4, Phase 2486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
5
EverolimusapprovedPhase 4, Phase 2, Phase 1, Phase 01797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
6
Miconazoleapproved, investigationalPhase 4, Phase 2, Phase 1, Phase 0302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
Methylphenidateapproved, investigationalPhase 4364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
8
DopamineapprovedPhase 4308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
9
TrametinibapprovedPhase 4, Phase 2, Phase 1111871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
10
Dasatinibapproved, investigationalPhase 4, Phase 2268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
11
Gefitinibapproved, investigationalPhase 4330184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
 
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
12
OlaparibapprovedPhase 4104763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
13
CrizotinibapprovedPhase 4, Phase 292877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
14
Vorinostatapproved, investigationalPhase 4238149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
15
Bortezomibapproved, investigational, experimentalPhase 4769179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
16
CeritinibapprovedPhase 4361032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib
17
Lapatinibapproved, investigational, Approved March 2007Phase 4, Phase 2, Phase 0294231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
18Dopamine AgentsPhase 43084
19Dopamine Uptake InhibitorsPhase 4925
20Protein Kinase InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Phase 03162
21Central Nervous System StimulantsPhase 41721
22Neurotransmitter Uptake InhibitorsPhase 42857
23Imatinib MesylatePhase 4, Phase 2, Phase 3, Phase 1577123596
24Antifungal AgentsPhase 4, Phase 2, Phase 1, Phase 03015
25Antibiotics, AntitubercularPhase 4, Phase 2, Phase 3, Phase 1, Phase 05971
26Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09140
27Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017220
28
Erlotinib HydrochloridePhase 4, Phase 2, Phase 1781183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
29Immunologic FactorsPhase 4, Phase 2, Phase 1, Phase 018483
30Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795
31Immunosuppressive AgentsPhase 4, Phase 2, Phase 1, Phase 010422
32Poly(ADP-ribose) Polymerase InhibitorsPhase 4250
33
ramucirumabPhase 462
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
34
Minocyclineapproved, investigationalPhase 317310118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
HMS2090D03
HSDB 3130
LMPK07000002
 
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline
Minocycline (USAN/INN)
Minocycline Hydrochloride
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
Ximino
minociclinum
minocycline
nchembio.559-comp1
35
Doxorubicinapproved, investigationalPhase 2, Phase 3, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
36
Tamsulosinapproved, investigationalPhase 3, Phase 1151106133-20-4129211
Synonyms:
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
106133-20-4
5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
AC1L2V76
BIDD:GT0261
C07124
C20H28N2O5S
CHEBI:9398
CHEMBL836
CID129211
D08560
DB00706
FT-0082894
Flomax
Flomax (TN)
Flowmax
 
HMS2090P15
Harnal
LS-31578
MolPort-003-850-388
NCGC00167442-01
STK626950
TAMSULOSIN
Tamsolusin
Tamsulon
Tamsulon (TN)
Tamsulosin
Tamsulosin (INN)
Tamsulosin Hydrochloride
Tamsulosin [INN:BAN]
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
UNII-G3P28OML5I
YM-617
37
IfosfamideapprovedPhase 2, Phase 33713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
38
Lamotrigineapproved, investigationalPhase 2, Phase 317984057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
39
ChlorhexidineapprovedPhase 2, Phase 339255-56-19552079, 2713
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
Betasept
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
CID9552079
Chlorhexidin
Chlorhexidin [Czech]
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine Base
Chlorhexidine Gluconate
Chlorhexidine [INN:BAN]
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
HMS1568M08
HSDB 7196
Hexadol
Hibiclens
Hibispray
Hibistat
I06-0621
I14-0050
IDI1_000761
KBio1_000761
 
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
LS-43917
Lisium (*Dihydrochloride*)
MK-412A
MLS001332387
MLS001332388
MLS002154209
Merfen-incolore
Merfen-incolore (TN)
MolPort-002-541-741
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
NSC526936
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
Oro-Clense
Paroex
Perichlor
Peridex
Periochip
Periogard
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
Prestwick_53
QTL1_000020
Rotersept
SMR000857146
SPBio_000210
SPBio_002185
STK089248
STOCK1S-18831
Savloclens
Savlon babycare
Sebidin A
Sodium Houttuyfonamide
Soretol
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Spectrum_000237
Sterido
Sterilon
Superspray
Tubulicid
UNII-R4KO0DY52L
chlorhexidine
40
MechlorethamineapprovedPhase 2, Phase 330951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
41
Cyclophosphamideapproved, investigationalPhase 2, Phase 3264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
42
DoxilApproved June 1999Phase 2, Phase 3, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
43Alkylating AgentsPhase 2, Phase 33582
44Topoisomerase InhibitorsPhase 2, Phase 3, Phase 14081
45Antineoplastic Agents, AlkylatingPhase 2, Phase 33406
46Isophosphamide mustardPhase 2, Phase 3371
47Adrenergic AntagonistsPhase 3, Phase 11253
48Carboxymethylcellulose SodiumPhase 3, Phase 1, Phase 2105
49Adrenergic AgentsPhase 3, Phase 14204
50Adrenergic alpha-AntagonistsPhase 3, Phase 1586

Interventional clinical trials:

(show top 50)    (show all 170)
idNameStatusNCT IDPhase
1NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by MethylphenidateCompletedNCT00169611Phase 4
2Stereotactic Body Radiotherapy for Spine TumorsActive, not recruitingNCT01347307Phase 4
3Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaNot yet recruitingNCT02645149Phase 4
4Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTSCompletedNCT02303769Phase 3
5Minocycline in Clinically Isolated Syndromes (CIS)CompletedNCT00666887Phase 3
6First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous NeurofibromasRecruitingNCT00921037Phase 2, Phase 3
7Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic PainRecruitingNCT02471339Phase 3
8Effect of Lamotrigine on Cognition in NF1RecruitingNCT02256124Phase 2, Phase 3
9Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryRecruitingNCT02180867Phase 2, Phase 3
10Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaActive, not recruitingNCT00346164Phase 3
11Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath TumorsTerminatedNCT00427583Phase 2, Phase 3
12Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform NeurofibromasCompletedNCT01412892Phase 2
13R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform NeurofibromasCompletedNCT00021541Phase 2
14Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform NeurofibromasCompletedNCT00076102Phase 2
15Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232TCompletedNCT02332902Phase 2
16Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2CompletedNCT01419639Phase 2
17Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1CompletedNCT00754780Phase 2
18Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT00973739Phase 2
19Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT02104323Phase 2
20Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)CompletedNCT01207687Phase 2
21Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01673009Phase 2
22Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2CompletedNCT00004437Phase 2
23Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath TumorsCompletedNCT00304083Phase 2
24Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable MeningiomaCompletedNCT00589784Phase 2
25Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
26Sorafenib and Dacarbazine in Soft Tissue SarcomaCompletedNCT00837148Phase 2
27S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorCompletedNCT00068367Phase 2
28Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaCompletedNCT00245102Phase 2
29Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict SensitivityCompletedNCT01024946Phase 2
30Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)RecruitingNCT02101736Phase 2
31Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasRecruitingNCT02129647Phase 2
32MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasRecruitingNCT02644512Phase 2
33Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by SurgeryRecruitingNCT02407405Phase 2
34AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsRecruitingNCT01362803Phase 1, Phase 2
35Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasRecruitingNCT02177825Phase 2
36Study of RAD001 for Treatment of NF2-related Vestibular SchwannomaRecruitingNCT01345136Phase 2
37PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)RecruitingNCT02390752Phase 1, Phase 2
38Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular SchwannomasRecruitingNCT01767792Phase 2
39Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway GliomaRecruitingNCT01553149Phase 2
40Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated TumorsRecruitingNCT02285439Phase 1, Phase 2
41Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT02601209Phase 1, Phase 2
42Multisession Radiosurgery for Optic Nerve Sheath MeningiomasRecruitingNCT02594709Phase 2
43PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT02584647Phase 1, Phase 2
44Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaRecruitingNCT02584309Phase 2
45Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial SarcomaRecruitingNCT02452554Phase 2
46Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue SarcomaRecruitingNCT01532687Phase 2
47Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsRecruitingNCT02352844Phase 2
48Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryRecruitingNCT02315625Phase 2
49A Study Looking at Targeted Therapy According to Tumor Markers for People With MeningiomasRecruitingNCT02523014Phase 2
50Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform NeurofibromasActive, not recruitingNCT01140360Phase 1, Phase 2

Search NIH Clinical Center for Neurofibromatosis


Cochrane evidence based reviews: neurofibromatosis 1

Genetic Tests for Neurofibromatosis

About this section

Anatomical Context for Neurofibromatosis

About this section

MalaCards organs/tissues related to Neurofibromatosis:

33
Brain, Bone, Skin, Breast, Testes, Lung, Prostate

Animal Models for Neurofibromatosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Neurofibromatosis:

38 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053778.6KIT, NF1, NF2, PTPN11, RASA1, RDX
2MP:00053718.6KIT, NF1, PDGFRA, PTPN11, RASA1, RET
3MP:00053888.1HRAS, KIT, NF1, NF2, PDGFRA, PTPN11
4MP:00053808.1EZR, KIT, NF1, NF2, PDGFRA, PTPN11
5MP:00053828.0HRAS, KIT, NF1, NF2, PDGFRA, PTPN11
6MP:00053817.8EZR, KIT, MLH1, NF1, PDGFRA, PMS2
7MP:00053797.7HRAS, KIT, MLH1, NF1, NF2, PDGFRA
8MP:00020067.7HRAS, KIT, MLH1, NF1, NF2, PDGFRA
9MP:00053867.6HRAS, KIT, MLH1, NF1, NF2, PDGFRA
10MP:00030127.4HRAS, KIT, OMG, PDGFRA, PTPN11, RASA1
11MP:00036317.2HRAS, KIT, NF1, NF2, PDGFRA, PTPN11
12MP:00053857.1APOBEC1, HRAS, KIT, NF1, PDGFRA, PTPN11
13MP:00053787.0EZR, HRAS, KIT, NF1, NF2, PDGFRA
14MP:00053877.0EZR, KIT, NF1, NF2, PDGFRA, PMS2
15MP:00028737.0APOBEC1, HRAS, KIT, NF1, OMG, PDGFRA
16MP:00053765.4APOBEC1, EZR, HRAS, KIT, MLH1, NF1
17MP:00107685.2APOBEC1, EZR, HRAS, KIT, MLH1, NF1

Publications for Neurofibromatosis

About this section

Articles related to Neurofibromatosis:

(show top 50)    (show all 1697)
idTitleAuthorsYear
1
Congenital pseudoarthrosis in a child with neurofibromatosis. (26670897)
2015
2
Pseudoangiomatous stromal hyperplasia with multinucleated stromal giant cells is neither exceptional in gynecomastia nor characteristic of neurofibromatosis type 1. (25586494)
2015
3
Giant malignant peripheral nerve sheath tumor with cauda equina syndrome and subarachnoid hemorrhage: Complications in a case of type 1 neurofibromatosis. (26283846)
2015
4
Strabismus in patients with neurofibromatosis typeA 1-associated optic pathway glioma. (26486023)
2015
5
(18)F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. (24097302)
2014
6
Anisometropia in children with neurofibromatosis type 1 and unilateral optic nerve glioma. (24924279)
2014
7
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. (24414536)
2014
8
Spontaneous intestinal haematoma associated with neurofibromatosis type-1. (23975920)
2013
9
Plasma S100I^ is not a useful biomarker for tumor burden in neurofibromatosis. (23261835)
2013
10
Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. (23412344)
2013
11
Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1. (23668869)
2013
12
Neurofibroma of the cervix presenting as cervical stenosis in a patient with neurofibromatosis type 1: a case report. (22317879)
2012
13
Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. (23035791)
2012
14
Spontaneous aortic rupture in a patient with neurofibromatosis type 1. (22493769)
2012
15
Screening for mutation site on the type I neurofibromatosis gene in a family. (22207399)
2012
16
Synchronous double tumor of breast cancer and gastrointestinal stromal tumor in a patient with neurofibromatosis type 1: report of a case. (22199319)
2011
17
Diffuse scalp malignant peripheral nerve sheath tumor with intracranial extension in a patient with neurofibromatosis type 1. (20655235)
2010
18
Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1. (20002172)
2010
19
Neurofibroma of the recurrent laryngeal nerve in a patient with known neurofibromatosis type 1. (19344601)
2009
20
Evolution and origin of HRS, a protein interacting with Merlin, the Neurofibromatosis 2 gene product. (20054405)
2009
21
Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2. (19573680)
2009
22
Diffusion-weighted imaging of retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1. (18460849)
2008
23
Anesthetic management of a parturient with neurofibromatosis 1 and Charcot-Marie-Tooth disease. (17869996)
2007
24
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. (15665300)
2005
25
Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. (15355893)
2004
26
A case of neurofibromatosis-Noonan syndrome with a central giant cell granuloma. (15356469)
2004
27
Neurofibromatosis type 1 tumour suppressor gene expression is deficient in psoriatic skin in vivo and in vitro: a potential link to increased Ras activity. (14996090)
2004
28
Independent NF1 mutations in two large families with spinal neurofibromatosis. (12566521)
2003
29
Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells. (12673723)
2003
30
Establishing priorities in neurofibromatosis research: a workshop summary. (11388764)
2001
31
Aetiology of spinal deformities in neurofibromatosis 1: new hypotheses. (11359370)
2001
32
An additional case of solitary subungual glomus tumor associated with neurofibromatosis 1. (10920593)
2000
33
Characterization of the Fugu rubripes NLK and FN5 genes flanking the NF1 (Neurofibromatosis type 1) gene in the 5' direction and mapping of the human counterparts. (10863097)
2000
34
Multiple intracranial and intraspinal meningiomas in the neurocristopathy (phacomatosis) type of neurofibromatosis]. (11378907)
2000
35
Exclusion of allelism of Noonan syndrome and neurofibromatosis-type 1 in a large family with Noonan syndrome-neurofibromatosis association. (8985499)
1996
36
Neurofibromatosis 2: loss of merlin's protective spell. (8791482)
1996
37
Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. (7868131)
1995
38
Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1). (7794530)
1995
39
Multiple transcripts of the neurofibromatosis type 1 gene in human brain and in brain tumours. (7874833)
1994
40
An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). (8089100)
1994
41
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. (1570015)
1992
42
A small deletion and an adjacent base exchange in a potential stem-loop region of the neurofibromatosis 1 gene. (1937470)
1991
43
44
45
46
47
48
49
50

Variations for Neurofibromatosis

About this section

Clinvar genetic disease variations for Neurofibromatosis:

5
id Gene Variation Type Significance SNP ID Assembly Location
1NF1NM_000267.3(NF1): c.4168C> T (p.Leu1390Phe)single nucleotide variantLikely pathogenic, Pathogenicrs199474789GRCh37Chr 17, 29585419: 29585419

Expression for genes affiliated with Neurofibromatosis

About this section
Search GEO for disease gene expression data for Neurofibromatosis.

Pathways for genes affiliated with Neurofibromatosis

About this section

Pathways related to Neurofibromatosis according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathwaysScoreTop Affiliating Genes
19.9NF1, PTPN11
2
Show member pathways
9.7NF1, RASA1, RASA2
3
Show member pathways
9.6SDHB, SDHC, SDHD
49.4HRAS, RASA1, RET
59.3HRAS, PTPN11, RASA1
6
Show member pathways
9.3HRAS, PTPN11, RASA1
7
Show member pathways
9.3HRAS, PTPN11, RASA1
89.3HRAS, PTPN11, RASA1
99.3HRAS, NF1, NF2, PDGFRA
109.1EZR, HRAS, NF1, RASA1
11
Show member pathways
9.1HRAS, NF1, PTPN11, RASA1
12
Show member pathways
9.0HRAS, KIT, RET
13
Show member pathways
9.0HRAS, NF1, RASA1, RASA2, SPRED1
14
Show member pathways
9.0HRAS, PDGFRA, PTPN11, RASA1
159.0HRAS, PTPN11, RASA1, RET
168.9HRAS, NF1, PDGFRA, RASA1, RASA2
178.8EZR, HRAS, PTPN11, RDX
188.7HRAS, KIT, PDGFRA, RET
198.7HRAS, KIT, PDGFRA, RET
20
Show member pathways
8.6HRAS, KIT, PDGFRA, PTPN11
21
Show member pathways
8.4HRAS, KIT, PTPN11, RASA1, SPRED1
228.4HRAS, KIT, MLH1, PDGFRA, RET
23
Show member pathways
7.9HRAS, KIT, NF1, PDGFRA, PTPN11, RASA1
24
Show member pathways
6.6EZR, HRAS, KIT, NF1, PDGFRA, PTPN11

GO Terms for genes affiliated with Neurofibromatosis

About this section

Cellular components related to Neurofibromatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1filopodiumGO:00301759.9EZR, NF2
2extrinsic component of membraneGO:00198989.8EZR, NF2

Biological processes related to Neurofibromatosis according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.6NF1, RET
2negative regulation of cell-matrix adhesionGO:000195310.5NF1, NF2, RASA1
3protein kinase A signalingGO:001073710.5EZR, RDX
4positive regulation of protein localization to early endosomeGO:190296610.4EZR, RDX
5negative regulation of Ras protein signal transductionGO:004658010.3NF1, RASA1, RASA2
6regulation of GTPase activityGO:004308710.3NF1, RASA1, RASA2
7positive regulation of phospholipase C activityGO:001086310.1KIT, PDGFRA
8megakaryocyte developmentGO:003585510.0KIT, PTPN11
9cellular response to thyroid hormone stimulusGO:00970679.9KIT, RDX
10transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.7KIT, PDGFRA, RET
11phosphatidylinositol-mediated signalingGO:00480159.7EZR, KIT, PDGFRA
12regulation of long-term neuronal synaptic plasticityGO:00481699.7HRAS, NF1
13epidermal growth factor receptor signaling pathwayGO:00071739.3HRAS, NF1, PDGFRA, PTPN11, RASA1
14activation of MAPKK activityGO:00001868.6HRAS, KIT, NF1, PDGFRA, RASA1, RASA2
15vascular endothelial growth factor receptor signaling pathwayGO:00480108.6HRAS, KIT, NF1, PDGFRA, RASA1, RASA2
16axon guidanceGO:00074118.6EZR, HRAS, KIT, RASA1, SPRED1
17MAPK cascadeGO:00001658.4HRAS, KIT, NF1, RASA1, RASA2, RET
18neurotrophin TRK receptor signaling pathwayGO:00480118.2HRAS, NF1, OMG, RASA1, RASA2, SPRED1
19fibroblast growth factor receptor signaling pathwayGO:00085438.1HRAS, KIT, NF1, PDGFRA, PTPN11, RASA1
20insulin receptor signaling pathwayGO:00082868.0HRAS, KIT, NF1, PDGFRA, PTPN11, RASA1
21signal transductionGO:00071658.0HRAS, KIT, NF1, RASA1, RASA2, RET
22innate immune responseGO:00450877.7HRAS, KIT, NF1, PDGFRA, PTPN11, RASA1

Sources for Neurofibromatosis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet